There has been a real interest recently in developing once-daily β2-adrenoceptor agonists
(ultra-long-acting β 2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic …

After the discovery of formoterol and salmeterol, new candidates for long-acting β2-
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …

Asthma is a worldwide chronic disorder that is characterised by airway inflammation and
hyper-responsiveness, which results in intermittent airflow obstruction and subsequent …

Background Long-acting β 2-adrenergic agonists (LABAs) are recommended in combination
with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective …

Introduction Asthma, a heterogeneous disease, is characterized by chronic airway
inflammation and hyperreactivity. β2-adrenoreceptor agonists (β2-agonists) remain pivotal …

Concerns about the safety of long-acting β2-agonist (LABA) therapy, has led to the
appearance of multiple publications and recommendations. This review critically examines …

Bronchodilators are central in the symptomatic management of asthma. It is likely that the
once-daily dosing of a bronchodilator would be a significant convenience and probably a …

BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and
recent evidence suggested a detrimental effect on asthma control as well as an increased …